

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/017921

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K39/395 A61K38/20 A61P35/02 //(A61K39/395, 38:20)		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, EMBASE, WPI Data, BIOSIS, PAJ		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DMOSZYNSKA A ET AL: "Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: Results of a pilot study" LEUKEMIA AND LYMPHOMA 1999 UNITED KINGDOM, vol. 34, no. 3-4, 1999, pages 335-340, XP009040439 ISSN: 1042-8194 abstract page 335, left-hand column, paragraph 1 - page 336, right-hand column, last paragraph page 338, left-hand column, last paragraph - page 339, right-hand column, paragraph 1 table 2 <div style="text-align: center; margin-top: 10px;">----- -/--</div>	1-39
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*G* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
29 November 2004	22/12/2004	
Name and mailing address of the ISA	Authorized officer	
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Ulbrecht, M	

INTERNATIONAL SEARCH REPORT

International Application No

/US2004/017921

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MORRISON V A: "Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia." EXPERT REVIEW OF ANTICANCER THERAPY. JUN 2001, vol. 1, no. 1, June 2001 (2001-06), pages 84-90, XP009040536 ISSN: 1473-7140 abstract page 87, left-hand column, paragraph 2</p>	1-39
Y	<p>KAY N E ET AL: "EVIDENCE FOR TUMOR REDUCTION IN REFRACTORY OR RELAPSED B-CLL PATIENTS WITH INFUSIONAL INTERLEUKIN-2" NOUVELLE REVUE FRANCAISE D'HEMATOLOGIE, vol. 30, no. 5-6, 1988, pages 475-478, XP001203900 & IVTH INTERNATIONAL WORKSHOP ON CHRONIC LYMPHOCYTIC LEUKEMIA, PARIS, FRANCE, SEPTEMBER 4-7, 1988. NOU ISSN: 0029-4810 abstract page 477, right-hand column, paragraph 2 - paragraph 3</p>	1-39
Y	<p>OSTERBORG ANDERS ET AL: "Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia" JOURNAL OF CLINICAL ONCOLOGY, vol. 15, no. 4, 1997, pages 1567-1574, XP009040592 ISSN: 0732-183X abstract page 1568, left-hand column, paragraph 3 page 1572, right-hand column, paragraph 2</p>	1-39
A	<p>WIERDA W G ET AL: "Immunotherapy of chronic lymphocytic leukemia" EXPERT REVIEW OF ANTICANCER THERAPY 2001 UNITED KINGDOM, vol. 1, no. 1, 2001, pages 73-83, XP009040447 ISSN: 1473-7140 page 76, left-hand column, paragraph 3 - page 77, left-hand column, paragraph 1</p> <p style="text-align: center;">----- -/--</p>	1-39

INTERNATIONAL SEARCH REPORT

International Application No

/US2004/017921

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BAIGENT G ET AL: "Recombinant Interleukin-2 (aldesleukin) for oncology and HIV disease and recombinant protein treatment (Fabrazyme) for Fabry's disease (No. 14 in a series of articles to promote a better understanding of the use of genetic engineering)" JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 95, no. 3, 2002, pages 277-282, XP002239728 ISSN: 0168-1656 the whole document</p>	1-39

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/017921

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-15, 28-32
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-15 and 28-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.